Assessing thrombophilia with activated charcoal for patients on DOACs
Thrombophilia Assessment Under Direct Oral Anticoagulants (DOAC): Efficacy of Activated Charcoal
This study is testing if activated charcoal can help improve blood tests for people on blood thinners like Apixaban and Rivaroxaban by making it easier to check for clotting disorders.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06171984 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of activated charcoal in adsorbing direct oral anticoagulants (DOACs) like Apixaban and Rivaroxaban to facilitate thrombophilia testing. It aims to address the challenges posed by DOACs on coagulation tests, which can interfere with the assessment of conditions like protein S deficiency and lupus anticoagulants. By reusing blood samples already analyzed in the laboratory, the study seeks to improve the accuracy of thrombophilia workups for patients on these medications.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have had their blood samples analyzed as part of routine care.
Not a fit: Patients with insufficient blood samples will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the ability to diagnose thrombophilia in patients taking DOACs, leading to better management of their condition.
How similar studies have performed: While the use of activated charcoal for this purpose is novel, recent studies have indicated its potential effectiveness in improving coagulation testing accuracy in patients on DOACs.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Adult subject (≥ 18 years of age) * Blood sample already analyzed in a usual way in the laboratory as part of the care * Subject not objecting to the reuse of his or her medical data for scientific research purposes. Exclusion criteria: - Insufficient sample
Where this trial is running
Strasbourg
- Laboratoire d'Hématologie - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Agathe HERB, PharmD
- Email: agathe.herb@chru-strasbourg.fr
- Phone: 33 3 88 12 75 53
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.